U.S., June 6 -- ClinicalTrials.gov registry received information related to the study (NCT07631052) titled 'Capecitabine in ER+/HER2-negative Breast Cancer' on Dec. 04, 2025.
Brief Summary: This is a Phase 2 study for patients with resected Stage I-III HR+/HER2-negative breast cancer with detected molecular residual disease (MRD+) following standard neo/adjuvant and locoregional therapy delivered with curative intent. In this study participants will be treated with capecitabine. Capecitabine will be administered orally at a dose of 500 mg 3 times daily for up to 12 months, or until the time of clinical recurrence, discontinuation due to toxicity, or withdrawal of consent. This study will have two stages, stage 1 would enroll up to 8 partic...